Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… we are excited by the potential of our next-generation Axiomer RNA editing technology. In addition to using this … this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and will develop selected genetic eye disease targets with Axiomer ® . The Company anticipates providing further …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …